MedTrace Logo

The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease

NCT07080775 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-11

No results posted yet for this study

Summary

This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease

Conditions

Interventions

DRUG

human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

5.0×10\^7 cells/mL, injection, once, 12 months

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-05
Primary Completion
2026-04-30
Completion
2029-08-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080775 on ClinicalTrials.gov